Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
Fidelity Disruptive Medicine ETF(FMED)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for FMED
10/28/2026: FMED (2-star) is currently NOT-A-BUY. Pass it for now.
Fidelity Disruptive Medicine ETF (FMED) provides targeted, actively managed exposure to companies leading technological change in the medical industry, such as genomic sequencing and robotic surgery. Its main strengths include the high-quality research and active management provided by Fidelity, which helps navigate the complexities of the biotech sector. It is best used as a satellite holding for long-term investors seeking higher growth potential within their portfolios. However, investors must monitor key risks such as high volatility, industry-specific regulatory changes, and interest rate sensitivity. It is most appropriate for growth-oriented investors who can tolerate significant price swings in pursuit of long-term sector transformation.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The fund focuses on innovative companies with long-term capital appreciation potential. |
| Momentum investor | Mixed fit | Momentum fit is conditional on a positive Upturn signal, as the fund is susceptible to growth-sector volatility. |
| Value investor | Weak fit | The fund prioritizes disruptive potential over current valuation metrics, which may not suit traditional value strategies. |
| Dividend/Income investor | Weak fit | The portfolio focuses on capital growth rather than income generation, and rarely holds high-dividend payers. |
| Low-risk investor | Weak fit | The thematic and high-growth nature of the underlying assets leads to significant volatility not suitable for low-risk portfolios. |
Investor Profile
Ideal Investor Profile
The ideal investor is a growth-oriented individual with a high tolerance for risk and a long-term investment horizon.
Suitability
FMED is best suited for long-term investors looking to complement a core portfolio with thematic exposure to medical innovation.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | High | Disruptive technology stocks often experience significant price swings based on clinical trials and regulatory news. |
| Market risk | Medium / high | Broad market corrections significantly impact high-growth thematic sectors. |
| Concentration | High | The focus on a narrow sector increases exposure to industry-specific risks and regulatory changes. |
| Tracking/expense | Low | As an active fund, tracking error is expected and managed, and the expense ratio is competitive for the strategy. |
| Liquidity | Medium | Smaller or emerging biotech companies can suffer from lower liquidity during market stress. |
| Business/sector quality | Medium / high | The success of many holdings is highly dependent on research outcomes and long-term capital sustainability. |
Risk Analysis
Volatility
FMED exhibits higher historical volatility than the broader equity market, consistent with its growth-focused thematic mandate.
Market Risk
The fund is sensitive to market-wide volatility and specifically to risks impacting the healthcare, biotech, and life sciences industries, including clinical trial outcomes and government regulation.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Sector | Healthcare (Biotech, Medical Devices, Life Sciences) | 95 | The portfolio is highly concentrated in innovative healthcare companies poised for growth through technological advancement. |
| Cash/collateral | Cash and Cash Equivalents | 5 | A small cash buffer is maintained for liquidity management and operational needs. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type ETF | Historic Profit 31.44% | Avg. Invested days 64 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | ETF Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/28/2026 |
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.